Dr. Gilberto Lopes is a medical oncologist and researcher who focuses on new anticancer drug development and global oncology. He has published more than 270 scientific papers and has led hundreds of clinical trials. Dr. Lopes was the main investigator of Keynote 42, a clinical trial that demonstrated the efficacy of the immunotherapy drug pembrolizumab in people living with lung cancer. This groundbreaking study led to one of the FDA approvals of pembrolizumab. Additionally, Dr. Lopes has contributed significantly to the development of several chemotherapies and targeted medications that address specific molecular changes in tumors. He also does research in cancer control, policy and health economics and is active in improving access to cancer medications in underserved settings.